Private Funding Impacts Public Reseach
In 2000, the Lustgarten Foundation joined the National Cancer Institute (NCI) to participate in the first ever NCI Pancreatic Cancer Progress Review Group (PRG) to develop a national agenda for pancreatic cancer research. When the Lustgarten Foundation was created in 1998, public funding for pancreatic cancer research was .05% of the available federal finding for cancer research, and the disease carried a 4% survival rate.
Focus on Patients
Advance research to deliver improved outcomes for patients.
Increase the impact of funding through the coordination of academic work with translational groups, industry and clinicians.
Expand the impact of Foundation funds by matching investments of partners and industry.
Recruit the best experts in the world from a variety of disciplines and fields to work on pancreatic cancer.
Based on recommendations from the PRG, the NCI developed an action plan to increase support and funding for pancreatic cancer. As part of this plan, the NCI committed to fund at least three Pancreatic Cancer Specialized Programs of Research Excellence (SPOREs) for five years. This more than doubled the annual commitment of the NCI to pancreatic cancer research. Over time, the Foundation’s support of pancreatic cancer research helped stimulate the NCI to increase its pancreatic cancer research funding to over $182 million in 2018 and inspired the creation of other pancreatic cancer organizations.
“We now know enough about pancreatic cancer to think about overcoming it because the history of medicine is that once one understands the disease, it’s only a matter of time before that disease is conquered.” – Bert Vogelstein, M.D., Lustgarten Foundation Distinguished Scholar